During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
Pharmaceutical company GlaxoSmithKline and direct-to-consumer genetic testing company 23andMe have formed a drug discovery collaboration deal.
The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.
The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.